Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Deep vein thrombosis.

Paul A Kyrle1, Sabine Eichinger

  • 1Medical University of Vienna, Department of Internal Medicine I, Währinger Gürtel 18-20, 1090 Vienna, Austria. paul.kyrle@meduniwien.ac.at

Lancet (London, England)
|March 30, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The incidence of early recurrent venous thromboembolism: a systematic review and meta-analysis.

Research and practice in thrombosis and haemostasis·2026
Same author

Large language models vs thrombosis experts: a comparative study on patient education and clinical decision-making in venous thromboembolism.

Journal of thrombosis and haemostasis : JTH·2025
Same author

Anticoagulation for cancer-associated venous thromboembolism: navigating between risks of recurrence and bleeding.

European heart journal·2025
Same author

Management of patients with venous thromboembolism and a high recurrence risk estimated by the Vienna Prediction Model: a prospective cohort study.

Research and practice in thrombosis and haemostasis·2025
Same author

Guidelines and guidance: what is the path forward for the ISTH?

Journal of thrombosis and haemostasis : JTH·2024
Same author

Correction to: Treatment of haemophilia in Austria.

Wiener klinische Wochenschrift·2024
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
Same journal

Dual mobility total hip replacement in fractures: stability promotes patient confidence.

Lancet (London, England)·2026
Same journal

Dual mobility versus standard cups in total hip replacement for displaced femoral neck fractures (Duality): an international, multicentre, randomised, controlled, superiority trial.

Lancet (London, England)·2026
See all related articles

Deep vein thrombosis (DVT) and pulmonary embolism are common. Prophylaxis with anticoagulation and diagnostic tools like D-dimer tests help manage and prevent these serious conditions.

Area of Science:

  • Cardiovascular Medicine
  • Hematology
  • Vascular Surgery

Background:

  • Deep vein thrombosis (DVT) and its complications, pulmonary embolism (PE) and post-thrombotic syndrome (PTS), are prevalent medical disorders.
  • Thrombosis can be spontaneous or triggered by surgery, trauma, or immobility, necessitating prophylactic measures.
  • Effective prophylaxis involves low-dose anticoagulation, particularly in at-risk populations.

Purpose of the Study:

  • To review the current understanding of deep vein thrombosis (DVT) and its sequelae.
  • To discuss diagnostic strategies, including imaging and serological markers.
  • To outline therapeutic approaches, including anticoagulation and risk factor modification.

Main Methods:

  • Review of existing literature on deep vein thrombosis (DVT), pulmonary embolism (PE), and post-thrombotic syndrome (PTS).

Related Experiment Videos

  • Analysis of diagnostic modalities such as ultrasonography, venography, and D-dimer testing.
  • Evaluation of prophylactic and therapeutic anticoagulation strategies, including low-molecular-weight heparin (LMWH) and vitamin K antagonists (VKAs).

    • Main Results:

    • Clinical risk assessment and D-dimer measurement are crucial for ruling out DVT, as only 25% of symptomatic patients have a confirmed thrombus.
    • Low-molecular-weight heparin (LMWH) followed by vitamin K antagonists (VKAs) effectively prevents thrombus progression and embolisation.
    • Duration of anticoagulation varies; 3-6 months suffice for many, while indefinite therapy benefits specific patient groups (e.g., antithrombin deficiency, lupus anticoagulant, homozygous defects, recurrent DVT).
    • In cancer patients, LMWH demonstrates superior efficacy and comparable safety to VKAs.
    • While women generally have a lower risk, pregnancy and hormonal therapies (oral contraceptives, HRT) significantly increase thrombosis risk.

    Conclusions:

    • Deep vein thrombosis (DVT) management requires a multi-faceted approach combining risk assessment, accurate diagnosis, and appropriate anticoagulation.
    • Individualized treatment duration and agent selection (LMWH vs. VKAs) are critical, especially in specific populations like cancer patients.
    • Awareness of risk factors, including hormonal influences and genetic predispositions, is essential for prevention and management.